MYRANDA WHITMAN: Open Payments
NPI 1841600608 · BLOOMINGTON, IL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$883 in 51 payments from 12 companies in 2025. Trend: 2023 $1,448 · 2024 $1,388 · 2025 $883
Food & beverage: $883
| Company | Payments | Amount |
|---|---|---|
| Neurocrine BioSciences, Inc. | 12 | $177 |
| ABBVIE INC. | 9 | $148 |
| Lundbeck LLC | 6 | $116 |
| Otsuka America Pharmaceutical, Inc. | 5 | $101 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 5 | $92 |
| Janssen Pharmaceuticals, Inc | 4 | $81 |
| Teva Pharmaceuticals USA, Inc. | 4 | $55 |
| Alkermes, Inc. | 2 | $36 |
| Almatica Pharma LLC | 1 | $25 |
| Axsome Therapeutics, Inc. | 1 | $20 |
Products named: INGREZZA, REXULTI, VRAYLAR, CAPLYTA, ABILIFY ASIMTUFII, UZEDY, INVEGA SUSTENNA, ARISTADA.
Industry payments across IL — which companies pay providers there.
